🟠 SYNTAX Score II

[calc_syntax2]

What is SYNTAX Score II?

The SYNTAX Score II is an advanced version of the original SYNTAX Score, designed to improve the prediction of long-term outcomes after revascularization. It incorporates both anatomical (from the original SYNTAX Score) and clinical variables (e.g., age, sex, renal function, left ventricular ejection fraction) to provide a more personalized risk assessment.

Key Variables in SYNTAX Score II

  • Anatomical SYNTAX Score: Derived from the original SYNTAX Score, which evaluates the complexity of coronary lesions.

  • Clinical Variables:

  • **Age**: Older patients have a higher risk.
    • Sex: Females may have different risk profiles.

    • Creatinine Clearance: Reduced renal function increases risk.

    • Left Ventricular Ejection Fraction (LVEF): Lower LVEF is associated with worse outcomes.

    • Unprotected Left Main Disease: Increases complexity and risk.

    • Peripheral Vascular Disease (PVD): Indicates systemic atherosclerosis.

    • Chronic Obstructive Pulmonary Disease (COPD): Associated with higher perioperative risk.

  • Clinical Applications

    • Personalized Decision-Making: SYNTAX Score II helps determine whether a patient should undergo PCI or CABG based on their risk profile.

    • Predicting Outcomes: It predicts 10-year mortality and 5-year major adverse cardiac events (MACE) with greater accuracy than the original SYNTAX Score.

    • Heart Team Collaboration: Facilitates discussions between interventional cardiologists and cardiac surgeons to optimize treatment strategies.

    Strengths

    • Incorporates both anatomical and clinical factors.

    • Provides a more personalized risk assessment.

    • Validated in large clinical trials, including the SYNTAX trial.

    Limitations

    • Requires detailed clinical and angiographic data.

    • Calculation can be complex without dedicated software.

    • May not account for all patient-specific factors (e.g., frailty, comorbidities).

    References

    Updated January 18, 2025